

FREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS

DR. ABDUL JABBAR, MBBS NISHTAR MEDICAL UNIVERSITY, MULTAN, PAKISTAN.

DR. ABDUL BASIT, MBBS NISHTAR MEDICAL UNIVERSITY, MULTAN, PAKISTAN.

DR. HAFIZ MUHAMMAD HANNAN AKBAR, MBBS NISHTAR MEDICAL UNIVERSITY, MULTAN, PAKISTAN.

ABSTRACT

Objective: To see the frequency of non-alcoholic fatty liver disease in type II diabetic patients. To see biochemical derangements in NAFLD patients. Study Design: Cross-sectional study. Setting: Diabetic Research Centre & outpatient department Nishtar Hospital Multan. Methodology: One hundred patients of either sex having type II diabetes mellitus attending diabetic out-patient department Nishtar Hospital Multan were included in the study. A pre-designed study pro-forma was filled in relevant investigations and clinical assessments were carried out in all cases. All the patients underwent abdominal ultrasonography. Data were entered in SPSS-20 and analyzed. Results: A total of 100 diabetic patients were studied. Out of these, 51 (51%) were female and 49 (49%) were male. Mean age of the patients was 47.93 ± 8.57 years. Fifty one (51%) of the diabetic patients were having fatty liver. Out of these 51 patients of fatty liver, 32 (62.75%) were female and 19 (37.25%) were male. Fatigue was seen in 49 (53.26%), generalized weakness in 48 (52.18%), heaviness right upper abdomen in 22 (64.70%) and pain right upper abdomen was seen in 20 (58.82%) of fatty liver patients while these were 43 (46.74%), 44 (47.82%), 12 (35.30%) and 14 (41.18%) in non-fatty liver patients respectively. Itching was noted in 19 (44.18%) patients of fatty liver while it was 24 (55.82%) in non-fatty liver patients. Serum triglyceride level more than 160 mg/dl in 47 (92.15%) patients of fatty liver while serum cholesterol level more than 200 mg/dl was seen in 24 (47.05%). Aspartate amino-transferase (AST) more than 35 u/l was noted in 7 (13.72%), alanine amino-transferase (ALT) more than 40 u/l was noted in 6 (11.76%) fatty liver patients while serum albumin and serum billirubin were within normal range in all fatty liver and non-fatty liver patients.

Conclusion: Nonalcoholic fatty liver disease (NAFLD) is more commonly seen in type II diabetic patients. Serum triglyceride and serum cholesterol are significantly raised in NAFLD patients. Raised ALT and AST is not a common finding in our NAFLD study patients. Diabetic patients having heaviness or pain right upper abdomen with raised serum triglycerides and cholesterol should be more closely observed for NAFLD and liver complications.

KEYWORDS: Non-alcoholic fatty liver disease (NAFLD), type II diabetes mellitus.

INTRODUCTION

Fatty liver is a problem which is commonly encountered in medical practice. It is defined as diffused accumulation of fats mainly triglycerides in the liver cells. Usually the fat contents increase more than 5% of the normal liver weight.¹ If there is only accumulation of fat it is called steatosis and when this fat accumulation is accompanied by necro-inflammatory changes in the liver it is called steato-hepatitis. Fatty liver is divided mainly into two categories.

1. Alcoholic fatty liver 2. Non-alcoholic fatty liver.

The term non-alcoholic fatty liver disease (NAFLD) includes spectrum of changes from steatosis alone to nonalcoholic steato-hepatitis. Diabetes mellitus is an important cause of NAFLD while other important causes are obesity, hepatitis C virus, hepatitis B virus, pregnancy and certain drugs especially amiodarone, synthetic estrogens, cortico-steroids and tamoxifen. Non-alcoholic fatty liver disease is also seen in patients with Wilson's disease and haemo-chromatosis. It occurs when more fat is transported to liver from other parts of the body especially intestine, where accumulation of fats exceeds than its degradation and when excess carbohydrates delivered to the liver are converted into fatty acids. Liver damage is produced due to accumulation of fats, oxidative stress of mitochondria and by release of inflammatory cytokines. In diabetics NAFLD is usually associated with metabolic syndrome which is characterized by insulin resistance, obesity, hyper-triglyceridemia and hypertension and some studies describe NAFLD as hepatic component of metabolic syndrome.² Various studies have reported variable prevalence rates of NAFLD in general population and in diabetic patients.²⁻⁷ It can occur at any age but mostly seen in age group of 40-60 years. It is commonly seen in obese persons and truncal obesity is main culprit. Fatty liver is usually asymptomatic but patients may present with fatigue, generalized weakness, jaundice, nausea, vomiting, loss of appetite, un-explained weight loss and itching. In advance stage patient can come with stigmata of chronic liver disease. Various biochemical derangements have also been described in NAFLD patients⁸. The definite diagnosis is based upon histological examination of liver tissue however it is an invasive and costly procedure and is associated with complications. The present study was designed to see the frequency and biochemical derangements of NAFLD patients in type II diabetics.

METHODOLOGY

It was a cross-sectional study which was done using non-probable purposive sampling. A total of 100 type II diabetic patients were randomly selected from diabetic out patient department at Nishtar Hospital Multan. Informed verbal consent was taken from each patient and pre-designed proforma was filled in. Alcoholics and anti-HCV positive patients were excluded from the study. The presenting complaints of the patients were recorded and clinical assessment was done. All the patients underwent abdominal ultrasonography for detection of fatty liver by a sonologist. Serum cholesterol, serum triglycerides, ALT, AST, serum alkaline phosphatase, serum albumin, serum billirubin and anti-HCV were done in all the cases. The data were entered and analyzed using computer program SPSS-20.

RESULTS

A total of 100 diabetic patients were studied. Out of these, 51(51%) were female and 49 (49%) were male. Age varied from 40-70 years and mean age of the patients was 47.13 ± 8.57 years. Fifty one (51%) of these patients

were having fatty liver. Out of these 51 patients, 32 (62.75%) were female and 19 (37.25%) were male as shown in Fig-1. Patients presented with various complaints as shown in Table-I. Serum albumin and serum billirubin were normal in all the study patients while other biochemical derangements in NAFLD patients are given in Table-II.

Complaints	Fatty liver patients	Non-fatty liver patients	P-value
Fatigue	49 (53.26%)	43 (46.74%)	0.77
Generalized weakness	48 (52.18%)	44 (47.82%)	0.78
Heaviness right upper abdomen	22 (64.70%)	12 (35.30%)	0.01
Pain right upper abdomen	20 (58.82%)	14 (41.18%)	0.21
Itching	19 (44.18%)	24 (55.82%)	0.23
Nausea	15 (60%)	10 (40%)	0.29
Anorexia	08 (53.34%)	07 (46.86%)	0.84

Table-I: Presenting complaints of fatty and non-fatty liver diabetic patients.

Table-II: Biochemical profile of f	atty and non fatty	liver diabetic patients
------------------------------------	--------------------	-------------------------

Investigations	Fatty liver patients	Non-fatty liver patients	P-value
Serum Triglycerides (more than 150 mg/dl)	47	39	0.65
Serum Cholesterol (more than 200 mg/dl)	24	18	0.18
Serum Alkaline Phosphatase (more than 306 u/l)	08	05	0.21
AST (more than 35 u/l)	07	04	0.23
ALT (more than 40u/l)	06	06	NA

DISCUSSION

Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder. It is mainly seen in obese and diabetic patients. Varying prevalence rates have been reported in various studies. A recent study from Japan in apparently healthy individuals has reported the prevalence of NAFLD as 29%.³ An Italian study reported it to be 20%.⁴ The frequency of NAFLD reported in general population of USA is 20%.⁵ A study from Karachi, Pakistan conducted by Luxmi et al,² in 120 diabetic patients described the frequency of NAFLD as 60.8% and Akber et al from Saudi Arabia as 55%⁶ in type II diabetics and in India it is 49% among diabetics as reported by Gupta et al.⁷ In present study frequency of NAFLD is 51% which is close to the study by Gupta et al and Akber et al. It is

pertinent to say that we have taken abdominal ultrasonography as a tool for detection of NAFLD which can only detect if the fat content of the liver is more than 33% and sensitivity of ultrasonography for detection of fatty liver is poor if the patient has fat content less than 33% of the liver weight. The frequency of NAFLD actually might have been high if we had done liver biopsy for the diagnosis of NAFLD.

Various studies describe NAFLD as asymptomatic it may be true in initial phase of NAFLD but patients may present with fatigue and heaviness in right upper abdomen later on. In present study fatigue was noted as chief complaint in 92 diabetics, out of these 49 (53.26%) were fatty liver patients. Generalized weakness was seen in 92, out of which 48 (52.18%) were of NAFLD. Here it is difficult to say whether these complaints were purely due to NAFLD or underlying diabetes mellitus as our study population was type II diabetic patients. Heaviness right upper abdomen 22 (64.70%) and pain right upper abdomen 20 (58.82%) was seen in fatty liver patients. A study by Wing-kin syn et al described fatigue as an important symptom and pain right upper abdomen in 33% of the patients.⁹ Heaviness and pain in right upper abdomen is due to stretching of the liver capsule which is correlated with the amount of fat present in the liver.^{8,10} Diabetes mellitus is an important risk factor for NAFLD. It is established that diabetes mellitus through insulin resistance leads to increased free fatty acid load to the liver consequently high triglyceride synthesis and increased secretion of triglyceride rich very low density lipoprotein by the liver. Hyper-triglyceridemia is strongly correlated with NAFLD and our study also supports this. Serum triglycerides were raised in 92.15% of fatty liver patients. Similarly serum cholesterol was raised in 47.05% of patients. The study by Luxmi et al² also reported raised serum triglyceride level in patients with fatty liver and same is the result from our study.

Serum alkaline phosphatase was raised in 15.68% of our study patients. Raised Alkaline phosphatase has been described in fatty liver patients especially in old females.¹¹ AST and ALT were raised in our study in only 7 (13.72%) and 6 (11.76%) fatty liver patients respectively, however raised ALT and AST have been reported in significant number of fatty liver patients in other studies.^{12,13} Raised ALT level is important finding in fatty liver patients¹ while raised ALT was not seen in significant number of NAFLD patients in our study and these findings support the study by Luxmi et al.² Normal ALT has also been reported in NAFLD by other studies.⁹ Mofrad¹⁴ reported that histologic spectrum is not significantly different in patients with the raised or normal ALT and normal values did not confirm freedom from steato-hepatitis.

CONCLUSION

Nonalcoholic fatty liver disease (NAFLD) is more commonly seen in type II diabetic patients. Serum triglyceride and serum cholesterol are significantly raised in NAFLD patients. Raised ALT and AST is not a common finding in our NAFLD study patients. Diabetic patients having heaviness or pain right upper abdomen with raised serum triglycerides and cholesterol should be more closely observed for NAFLD and liver complications.

Suggestions:

- 1. Type II diabetic patients should also be monitored for the development of NAFLD and its complications.
- 2. Anti-HCV positive type II diabetic patients having fatty liver should be more carefully looked for sequelae of fatty liver.

REFERENCES

- Sherlock S, Dooley J. Nutritional and metabolic liver diseases. In: Diseases of the liver and biliary system. 11th edition; Blackwell publishing 2002;423-52.
- Luxmi S, Sattar RA, Ara J. Association of non-alcoholic fatty liver with type II diabetes mellitus. JLUMHS 2008;188-193.
- 3. Jimba S, Nakagami T, Takahashi M. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-45.
- 4. Bedogni G, Miglioli L, Masutti F. Prevalence of and risk factors for non-alcoholic fatty liver disease: the Diaonysos nutrition and liver study. Hepatology 2005;42:44-52.
- Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the 3rd National health and nutrition examination survey. JAMA 2002;287:356-9.
- Akber DH, Kawther AH. Non-alcoholic fatty liver disease in Saudi type II diabetic subjects attending a medical outpatient clinic. Diabetes Care 2003;26:3351-65.
- 7. Gupte P, Amarapukar D, Agal S, Baijal R, Kulshreshtta P, Pramik S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gasteroentrol Hepatol 2004;19:854-58.
- Podolsky DK. Infiltrative, genetic and metabolic diseases affecting the liver: In; Kasper DL, Fauci NS, Longo DL, Braunwald E, Hauser SL, Jameson JL. Harrison's principles of Internal Medicine. McGraw Hill Medical Publishing; 16th edition 2005;Vol II:1869-73.
- 9. Syn WK, Nightingale P, Bateman JM. Non-alcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. Hepatol Int 2008;2:190-95.
- Bacon BR, Farahvash MJ, Janney CG, Newuschwander-tetri BA. Non-alcoholic steato-hepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-09.
- Pantsari MW, Harrison SA. Non-alcoholic fatty liver disease presenting with an isolated elevated Alkaline Phosphatase [Liver, Pancrease and biliary tract: Clinical Research]. J Clinical Gasteroenterol 2006;40:633-5.
- Deng HM, Xiao CQ, Par HL. Analysis of associated factors in type II diabetic patients with fatty liver. J Clin Intern Med 2003;20:22-5.
- Vazarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine amino transferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:1889-95.
- Mafrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA. Clinical and histological spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.